Enveric Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
ENVB$1.42+1.7%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash | $4,908,769 | $4,677,491 |
| Prepaid expenses and other current assets | 466,330 | 259,216 |
| Total current assets | 5,375,099 | 4,936,707 |
| Other assets: | ||
| Property and equipment, net | 119,927 | 159,234 |
| Deferred offering costs, non-current | 26,438 | — |
| Total other assets | 146,365 | 159,234 |
| Total assets | $5,521,464 | $5,095,941 |
| LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $280,315 | $581,020 |
| Due to related parties | — | 99,875 |
| Accrued expenses and other current liabilities | 180,361 | 237,505 |
| Total current liabilities | 460,676 | 918,400 |
| Commitments and contingencies (Note 9) | - | |
| Mezzanine equity | ||
| Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Total mezzanine equity | — | — |
| Shareholders’ equity | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value, 100,000,000 shares authorized, 1,887,535 and 1,061,533 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 18,875 | 10,615 |
| Additional paid-in capital | 122,108,934 | 119,593,456 |
| Accumulated deficit | (116,479,965) | (114,846,492) |
| Accumulated other comprehensive loss | (587,056) | (580,038) |
| Total shareholders’ equity | 5,060,788 | 4,177,541 |
| Total liabilities, mezzanine equity, and shareholders’ equity | $5,521,464 | $5,095,941 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses | ||
| General and administrative | $1,249,961 | $1,360,138 |
| Research and development | 345,969 | 746,371 |
| Depreciation and amortization | 37,240 | 81,024 |
| Total operating expenses | 1,633,170 | 2,187,533 |
| Loss from operations | (1,633,170) | (2,187,533) |
| Other (expense) income | ||
| Other income | — | 2,565 |
| Interest (expense) income, net | (303) | 2 |
| Total other (expense) income | (303) | 2,567 |
| Net loss before income taxes | (1,633,473) | (2,184,966) |
| Income tax expense | — | — |
| Net loss | (1,633,473) | (2,184,966) |
| Other comprehensive loss | ||
| Foreign currency translation | (7,018) | (3,487) |
| Comprehensive loss | $(1,640,491) | $(2,188,453) |
| Net loss per share - basic and diluted | $(1.08) | $(14.58) |
| Weighted average shares outstanding, basic and diluted | 1,510,401 | 149,815 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
| Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Equity | |
| Balance at January 1, 2026 | 1,061,533 | $10,615 | $119,593,456 | $(114,846,492) | $(580,038) | $4,177,541 |
| Issuance of common stock and warrants in Private Placement, net of offering costs of $368,990 | 328,802 | 3,288 | 1,140,739 | — | — | 1,144,027 |
| Issuance of common stock for cash pursuant to ATM Agreement, net of offering costs of $54,484 | 497,200 | 4,972 | 1,286,066 | — | — | 1,291,038 |
| Stock based compensation | — | — | 88,673 | — | — | 88,673 |
| Foreign exchange translation loss | — | — | — | — | (7,018) | (7,018) |
| Net loss | — | — | — | (1,633,473) | — | (1,633,473) |
| Balance at March 31, 2026 | 1,887,535 | $18,875 | $122,108,934 | $(116,479,965) | $(587,056) | $5,060,788 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
| Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Equity | |
| Balance at January 1, 2025 | 56,501 | 565 | 108,261,264 | (106,074,505) | (594,517) | $1,592,807 |
| Issuance of common stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487 | 102,444 | 1,024 | 4,243,443 | — | — | 4,244,467 |
| Issuance of common shares for vested RSAs | 1,215 | 12 | (12) | — | — | — |
| Issuance of common shares for exercise of warrants | 38,528 | 385 | 74,659 | — | — | 75,044 |
| Issuance of round up shares | 7,283 | 73 | (73) | — | — | — |
| Stock based compensation | — | — | 193,848 | — | — | 193,848 |
| Foreign exchange translation loss | — | — | — | — | (3,487) | (3,487) |
| Net loss | — | — | — | (2,184,966) | — | (2,184,966) |
| Balance at March 31, 2025 | 205,971 | $2,059 | $112,773,129 | $(108,259,471) | $(598,004) | $3,917,713 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.